{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:08:58Z","timestamp":1785247738820,"version":"3.55.0"},"reference-count":27,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Tyrosine kinase 2 (TYK2), a key part of the inflammatory cascade responses, plays an integral role in the pathogenesis of psoriasis. Socrodeucitinib, an oral, TYK2 allosteric inhibitor, selectively inhibits TYK2 cytokine signalling pathways in psoriasis pathogenesis.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate the efficacy and safety of socrodeucitinib in patients with moderate\u2010to\u2010severe plaque psoriasis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In this phase 2, double\u2010blind, placebo\u2010controlled trial, 125 patients were randomly assigned (1:1:1) to receive socrodeucitinib at 6\u2009mg, 12\u2009mg or placebo orally, once daily, for 12\u2009weeks. The primary endpoint was the proportion of patients with a 75% or greater reduction from the baseline in the Psoriasis Area and Severity Index (PASI) score at week 12.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n At week 12, significantly more patients treated with socrodeucitinib achieved a 75% reduction from baseline in PASI score compared with placebo (28.6% at 6\u2009mg, 72.1% at 12\u2009mg vs. 7.5% for placebo,\n p<\/jats:italic>\n \u2009<\u20090.05 and\n p<\/jats:italic>\n \u2009<\u20090.001, respectively). At the 12\u2009mg dose, socrodeucitinib resulted in significantly higher response rates compared to placebo, with 46.5% of patients achieving PASI 90 (\n p<\/jats:italic>\n \u2009<\u20090.001) and 11.6% achieving PASI 100 (\n p<\/jats:italic>\n \u2009<\u20090.05). The treatment of socrodeucitinib also led to significantly higher proportions of patients achieving sPGA responses of 0 or 1 compared to placebo: 33.3% at 6\u2009mg and 65.1% at 12\u2009mg versus 10% for placebo (\n p<\/jats:italic>\n \u2009<\u20090.05 and\n p<\/jats:italic>\n \u2009<\u20090.001, respectively). Most common adverse events included upper respiratory tract infection which demonstrated a certain dose dependency. Most treatment\u2010related adverse events were mild or moderate, and serious adverse events were infrequent, with no clinically meaningful abnormal trend in laboratory parameters.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Socrodeucitinib demonstrated significantly greater clearing of psoriasis plaques compared to placebo in patients with moderate\u2010to\u2010severe plaque psoriasis and illustrated a favourable safety and tolerability profile, warranting further investigation in longer\u2010duration and larger trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jdv.70643","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:34:00Z","timestamp":1785245640000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A randomized phase 2 trial of socrodeucitinib in moderate\u2010to\u2010severe plaque psoriasis"],"prefix":"10.1111","author":[{"given":"Ling","family":"Han","sequence":"first","affiliation":[{"name":"Department of Dermatology Huashan Hospital, Fudan University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songmei","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital) Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Dermatology Shanghai Skin Disease Hospital Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifa","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Northeast International Hospital Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Dermatology Hospital of Southern Medical University Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Dermatology Hospital of Jiangxi Province Nanchang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology Henan Provincial People's Hospital Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ci","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology The First Affiliated Hospital of Wannan Medical College Wuhu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Taizhou Municipal Hospital Taizhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rixin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nanyang First People's Hospital Nanyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Second Hospital of Jiaxing City Jiaxing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Dermatology Wuhan First Hospital Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology The First Affiliated Hospital of Chongqing Medical University Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Peking University Third Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiechi","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Dermatology Renmin Hospital of Wuhan University Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Second People's Hospital of Chengdu Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Affiliated Hospital of Guizhou Medical University Guizhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zudong","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Dermatology People's Hospital of Shiyan City Shiyan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9384-8793","authenticated-orcid":false,"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Dermatology The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkai","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Second Affiliated Hospital of Xiamen Medical College Xiamen China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Development Center Jiangsu Hansoh Pharmaceutical Group Co., Ltd China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunting","family":"Wu","sequence":"additional","affiliation":[{"name":"Clinical Development Center Jiangsu Hansoh Pharmaceutical Group Co., Ltd China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Jiangsu Hansoh Pharmaceutical Group Co., Ltd China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Jiangsu Hansoh Pharmaceutical Group Co., Ltd China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Huashan Hospital, Fudan University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"10281","key":"e_1_2_14_2_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths CEM","year":"2021","journal-title":"Lancet"},{"key":"e_1_2_14_3_1","volume-title":"Global report on psoriasis","author":"World Health O","year":"2016"},{"issue":"19","key":"e_1_2_14_4_1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong AW","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"e_1_2_14_5_1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"7","author":"Sbidian E","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"40","key":"e_1_2_14_6_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027368","article-title":"Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: a systematic review and meta\u2010analysis","volume":"100","author":"Zou A","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"e_1_2_14_7_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.clindermatol.2023.08.003","article-title":"Biologic therapies for psoriasis and eyes","volume":"41","author":"Burek\u2010Michalska A","year":"2023","journal-title":"Clin Dermatol"},{"issue":"1","key":"e_1_2_14_8_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase\u2013signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger JG","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"e_1_2_14_9_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop KL","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"e_1_2_14_10_1","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark JD","year":"2014","journal-title":"J Med Chem"},{"issue":"12","key":"e_1_2_14_11_1","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz DM","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"e_1_2_14_12_1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40264-023-01333-0","article-title":"Managing cardiovascular and cancer risk associated with JAK inhibitors","volume":"46","author":"Yang V","year":"2023","journal-title":"Drug Saf"},{"key":"e_1_2_14_13_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell MD","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_2_14_14_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4110\/in.2017.17.1.25","article-title":"Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies","volume":"17","author":"Kim DH","year":"2017","journal-title":"Immune Netw"},{"issue":"2","key":"e_1_2_14_15_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune\u2010mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?","volume":"77","author":"Baker KF","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"e_1_2_14_16_1","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.1074\/jbc.M114.619502","article-title":"Tyrosine kinase 2\u2010mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its Pseudokinase domain","volume":"290","author":"Tokarski JS","year":"2015","journal-title":"J Biol Chem"},{"issue":"1","key":"e_1_2_14_17_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52\u2010week, randomized, double\u2010blinded, phase 3 program fOr evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober B","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"e_1_2_14_18_1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with Zasocitinib (TAK\u2010279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong AW","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"e_1_2_14_19_1","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis","volume":"149","author":"Catlett IM","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_14_20_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1264667","article-title":"The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta\u2010analysis of randomized controlled trials","volume":"10","author":"Qiu J","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"e_1_2_14_21_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043391","article-title":"Tyk2 targeting in immune\u2010mediated inflammatory diseases","volume":"24","author":"Rusi\u00f1ol L","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"e_1_2_14_22_1","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor Deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda A","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"14","key":"e_1_2_14_23_1","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp K","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_2_14_24_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.det.2024.02.013","article-title":"Oral psoriasis therapies","volume":"42","author":"James J","year":"2024","journal-title":"Dermatol Clin"},{"issue":"2","key":"e_1_2_14_25_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF\u201006826647 demonstrates efficacy and an acceptable safety profile in participants with moderate\u2010to\u2010severe plaque psoriasis in a phase 2b, randomized, double\u2010blind, placebo\u2010controlled study","volume":"87","author":"Tehlirian C","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"e_1_2_14_26_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel C","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"e_1_2_14_27_1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta\u2010analysis across disease indications","volume":"82","author":"Russell MD","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_14_28_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2025.09.036","article-title":"Novel TYK2 inhibitor D\u20102570 in moderate\u2010to\u2010severe plaque psoriasis: a randomized, double\u2010blind, placebo\u2010controlled, phase 2 trial","volume":"94","author":"Zhang J","year":"2025","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70643","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70643","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:34:04Z","timestamp":1785245644000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":27,"alternative-id":["10.1111\/jdv.70643"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70643","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"2026-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jdv.70643"}}